| Year |
Citation |
Score |
| 2023 |
Butrovich MA, Reaves AC, Heyward J, Moore TJ, Alexander GC, Inker LA, Nolin TD. Inclusion of Participants with Chronic Kidney Disease and Other Kidney-Related Considerations during Clinical Drug Development. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 36723359 DOI: 10.2215/CJN.0000000000000105 |
0.321 |
|
| 2021 |
Franchetti Y, Nolin TD. Dose Optimization in Kidney Disease: Opportunities for PBPK Modeling and Simulation. Journal of Clinical Pharmacology. S36-S51. PMID 33205428 DOI: 10.1002/jcph.1741 |
0.303 |
|
| 2020 |
Perazella MA, Nolin TD. Adverse Drug Effects in Patients with CKD: Primum Non Nocere. Clinical Journal of the American Society of Nephrology. 15: 1075-1077. PMID 32611663 DOI: 10.2215/Cjn.08890620 |
0.313 |
|
| 2020 |
Jawale CV, Ramani K, Li DD, Coleman BM, Oberoi RS, Kupul S, Lin L, Desai JV, Delgoffe GM, Lionakis MS, Bender FH, Prokopienko AJ, Nolin TD, Gaffen SL, Biswas PS. Restoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease. Science Translational Medicine. 12. PMID 32554707 DOI: 10.1126/Scitranslmed.Aay5691 |
0.333 |
|
| 2020 |
Kimber C, Zhang S, Johnson C, West RE, Prokopienko AJ, Mahnken JD, Yu AS, Hoofnagle AN, Ir D, Robertson CE, Miyazaki M, Chonchol M, Jovanovich A, Kestenbaum B, Frank DN, ... Nolin TD, et al. Randomized, Placebo-controlled Trial of Rifaximin Therapy for Lowering Gut-derived Cardiovascular Toxins and Inflammation in Chronic Kidney Disease Kidney. DOI: 10.34067/Kid.0003942020 |
0.333 |
|
| 2019 |
Prokopienko AJ, West RE, Schrum DP, Stubbs JR, Leblond FA, Pichette V, Nolin TD. Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease. Scientific Reports. 9: 15901. PMID 31685846 DOI: 10.1038/S41598-019-52032-9 |
0.359 |
|
| 2019 |
Prokopienko AJ, West RE, Stubbs JR, Nolin TD. Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease. Journal of Pharmaceutical and Biomedical Analysis. 174: 618-624. PMID 31276982 DOI: 10.1016/J.Jpba.2019.06.033 |
0.321 |
|
| 2019 |
Casal MA, Nolin TD, Beumer JH. Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing. Clinical Journal of the American Society of Nephrology. 14: 587-595. PMID 30890575 DOI: 10.2215/Cjn.11721018 |
0.389 |
|
| 2019 |
Stubbs JR, Stedman MR, Liu S, Long J, Franchetti Y, West RE, Prokopienko AJ, Mahnken JD, Chertow GM, Nolin TD. Trimethylamine -Oxide and Cardiovascular Outcomes in Patients with End-stage Kidney Disease Receiving Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology : Cjasn. PMID 30665924 DOI: 10.2215/Cjn.06190518 |
0.304 |
|
| 2018 |
Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM. Use of physiologically-based pharmacokinetic (PBPK) modeling to evaluate the effect of chronic kidney disease on the disposition of hepatic CYP2C8 and OATP1B drug substrates. Clinical Pharmacology and Therapeutics. PMID 30074626 DOI: 10.1002/Cpt.1205 |
0.423 |
|
| 2018 |
Ghannoum M, Hoffman RS, Gosselin S, Nolin TD, Lavergne V, Roberts DM. Use of extracorporeal treatments in the management of poisonings. Kidney International. PMID 29958694 DOI: 10.1016/J.Kint.2018.03.026 |
0.336 |
|
| 2018 |
Johnson C, Prokopienko AJ, West RE, Nolin TD, Stubbs JR. Decreased Kidney Function is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine N-oxide Concentrations in Mice. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 29915157 DOI: 10.1124/Dmd.118.081646 |
0.317 |
|
| 2018 |
Nolin TD, Perazella MA. Introduction to Nephropharmacology for the Clinician: A New CJASN Series Clinical Journal of the American Society of Nephrology. 13: 1083-1084. PMID 29661769 DOI: 10.2215/Cjn.03180318 |
0.416 |
|
| 2018 |
Hudson JQ, Nolin TD. Pragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is Turning. Advances in Chronic Kidney Disease. 25: 14-20. PMID 29499882 DOI: 10.1053/J.Ackd.2017.10.003 |
0.391 |
|
| 2018 |
Choi YJ, Zhou D, Barbosa A, Niu Y, Guan X, Xu M, Ren S, Nolin T, Liu Y, Xie W. Activation of constitutive androstane receptor ameliorates renal ischemia-reperfusion induced liver and kidney injury. Molecular Pharmacology. PMID 29351922 DOI: 10.1124/Mol.117.111146 |
0.304 |
|
| 2018 |
Prokopienko AJ, Nolin TD. Microbiota-derived uremic retention solutes: perpetrators of altered nonrenal drug clearance in kidney disease. Expert Review of Clinical Pharmacology. 11: 71-82. PMID 28905671 DOI: 10.1080/17512433.2018.1378095 |
0.404 |
|
| 2017 |
Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney International Reports. 2: 1050-1058. PMID 29270514 DOI: 10.1016/J.Ekir.2017.06.002 |
0.352 |
|
| 2017 |
Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM. Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clinical Pharmacology and Therapeutics. PMID 28990182 DOI: 10.1002/Cpt.807 |
0.386 |
|
| 2016 |
Nolin TD. Vancomycin and the Risk of AKI: Now Clearer than Mississippi Mud. Clinical Journal of the American Society of Nephrology. 11: 2101-2103. PMID 27895133 DOI: 10.2215/Cjn.11011016 |
0.348 |
|
| 2016 |
Alshogran OY, Nolin TD. Implications of Kidney Disease on Metabolic Reduction. Current Drug Metabolism. PMID 27262337 DOI: 10.2174/1389200217666160603131320 |
0.426 |
|
| 2016 |
Roumelioti ME, Nolin T, Unruh ML, Argyropoulos C. Revisiting the Middle Molecule Hypothesis of Uremic Toxicity: A Systematic Review of Beta 2 Microglobulin Population Kinetics and Large Scale Modeling of Hemodialysis Trials In Silico Plos One. 11. PMID 27055286 DOI: 10.1371/Journal.Pone.0153157 |
0.305 |
|
| 2016 |
Vijayan A, Faubel S, Askenazi DJ, Cerda J, Fissell WH, Heung M, Humphreys BD, Koyner JL, Liu KD, Mour G, Nolin TD, Bihorac A. Clinical Use of the Urine Biomarker [TIMP-2] × [IGFBP7] for Acute Kidney Injury Risk Assessment. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. PMID 26948834 DOI: 10.1053/J.Ajkd.2015.12.033 |
0.363 |
|
| 2016 |
Yoshida K, Sun B, Zhang L, Zhao P, Abernethy D, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM. Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5. Clinical Pharmacology and Therapeutics. PMID 26800425 DOI: 10.1002/Cpt.337 |
0.428 |
|
| 2016 |
Anseeuw K, Mowry JB, Burdmann EA, Ghannoum M, Hoffman RS, Gosselin S, Lavergne V, Nolin TD. Extracorporeal Treatment in Phenytoin Poisoning: Systematic Review and Recommendations from the EXTRIP (Extracorporeal Treatments in Poisoning) Workgroup. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 67: 187-97. PMID 26578149 DOI: 10.1053/J.Ajkd.2015.08.031 |
0.323 |
|
| 2015 |
de Caestecker M, Humphreys BD, Liu KD, Fissell WH, Cerda J, Nolin TD, Askenazi D, Mour G, Harrell FE, Pullen N, Okusa MD, Faubel S. Bridging Translation by Improving Preclinical Study Design in AKI. Journal of the American Society of Nephrology : Jasn. PMID 26538634 DOI: 10.1681/Asn.2015070832 |
0.33 |
|
| 2015 |
Alshogran OY, Urquhart BL, Nolin TD. Downregulation of Hepatic Carbonyl Reductase Type 1 in End-Stage Renal Disease. Drug Metabolism Letters. 9: 111-8. PMID 26282591 DOI: 10.2174/1872312809666150818111626 |
0.342 |
|
| 2015 |
Stubbs JR, House JA, Ocque AJ, Zhang S, Johnson C, Kimber C, Schmidt K, Gupta A, Wetmore JB, Nolin TD, Spertus JA, Yu AS. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. Journal of the American Society of Nephrology : Jasn. PMID 26229137 DOI: 10.1681/Asn.2014111063 |
0.318 |
|
| 2015 |
Walsh DR, Nolin TD, Friedman PA. Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins. Pharmacological Reviews. 67: 656-80. PMID 26092975 DOI: 10.1124/Pr.115.010728 |
0.329 |
|
| 2015 |
Juurlink DN, Gosselin S, Kielstein JT, Ghannoum M, Lavergne V, Nolin TD, Hoffman RS. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Annals of Emergency Medicine. 66: 165-81. PMID 25986310 DOI: 10.1016/J.Annemergmed.2015.03.031 |
0.304 |
|
| 2015 |
Ghannoum M, Laliberté M, Nolin TD, Mactier R, Lavergne V, Hoffman RS, Gosselin S, Anseeuw K, Bhalla A, Burdmann EA, Calello DP, Dargan PI, Decker BS, Galvao TF, Goldfarb DS, et al. Extracorporeal treatment for valproic acid poisoning: Systematic review and recommendations from the EXTRIP workgroup Clinical Toxicology. 53: 454-465. PMID 25950372 DOI: 10.3109/15563650.2015.1035441 |
0.307 |
|
| 2015 |
Perry Wilson F, Nolin TD, Berns JS. Drugs, Dialysis, Decisions, and Data: A Walk through the Minefield of Nephropharmacology. Seminars in Dialysis. 28: 323-4. PMID 25929704 DOI: 10.1111/Sdi.12390 |
0.307 |
|
| 2015 |
Naud J, Dumayne C, Nolin TD, Leblond FA, Pichette V. [Drug pharmacokinetics in renal failure: What's new?]. NÉPhrologie & théRapeutique. 11: 144-51. PMID 25861715 DOI: 10.1016/J.Nephro.2014.12.006 |
0.426 |
|
| 2015 |
Calello DP, Liu KD, Wiegand TJ, Roberts DM, Lavergne V, Gosselin S, Hoffman RS, Nolin TD, Ghannoum M. Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup. Critical Care Medicine. 43: 1716-30. PMID 25860205 DOI: 10.1097/Ccm.0000000000001002 |
0.304 |
|
| 2015 |
Nolin TD. A Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKD. Seminars in Dialysis. 28: 325-9. PMID 25855244 DOI: 10.1111/Sdi.12374 |
0.423 |
|
| 2015 |
Decker BS, Goldfarb DS, Dargan PI, Friesen M, Gosselin S, Hoffman RS, Lavergne V, Nolin TD, Ghannoum M. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. Clinical Journal of the American Society of Nephrology : Cjasn. 10: 875-87. PMID 25583292 DOI: 10.2215/Cjn.10021014 |
0.332 |
|
| 2015 |
Hudson JQ, Nolin TD. Estimated GFR and cystatin C for drug dosing: moving beyond proof of concept to clinical translation? American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 65: 534-6. PMID 25542411 DOI: 10.1053/J.Ajkd.2014.11.006 |
0.305 |
|
| 2015 |
Roberts DM, Yates C, Megarbane B, Winchester JF, Maclaren R, Gosselin S, Nolin TD, Lavergne V, Hoffman RS, Ghannoum M. Recommendations for the role of extracorporeal treatments in the management of acute methanol poisoning: a systematic review and consensus statement. Critical Care Medicine. 43: 461-72. PMID 25493973 DOI: 10.1097/Ccm.0000000000000708 |
0.314 |
|
| 2015 |
Limdi NA, Nolin TD, Booth SL, Centi A, Marques MB, Crowley MR, Allon M, Beasley TM. Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 65: 701-9. PMID 25468385 DOI: 10.1053/J.Ajkd.2014.11.004 |
0.306 |
|
| 2015 |
Thomson BK, Nolin TD, Velenosi TJ, Feere DA, Knauer MJ, Asher LJ, House AA, Urquhart BL. Effect of CKD and dialysis modality on exposure to drugs cleared by nonrenal mechanisms. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 65: 574-82. PMID 25453994 DOI: 10.1053/J.Ajkd.2014.09.015 |
0.415 |
|
| 2015 |
Alshogran OY, Naud J, Ocque AJ, Leblond FA, Pichette V, Nolin TD. Effect of experimental kidney disease on the functional expression of hepatic reductases. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 100-6. PMID 25332430 DOI: 10.1124/Dmd.114.061150 |
0.382 |
|
| 2015 |
Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leypoldt JK, Witcher JW, Zineh I, Archdeacon P, Roy-Chaudhury P, et al. Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative. Clinical Journal of the American Society of Nephrology : Cjasn. 10: 159-64. PMID 25189923 DOI: 10.2215/Cjn.05630614 |
0.399 |
|
| 2014 |
Tortorici MA, Cutler DL, Hazra A, Nolin TD, Rowland-Yeo K, Venkatakrishnan K. Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease. Journal of Clinical Pharmacology. PMID 25501531 DOI: 10.1002/Jcph.444 |
0.435 |
|
| 2014 |
Mactier R, Laliberté M, Mardini J, Ghannoum M, Lavergne V, Gosselin S, Hoffman RS, Nolin TD. Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 64: 347-58. PMID 24998037 DOI: 10.1053/J.Ajkd.2014.04.031 |
0.341 |
|
| 2014 |
Tortorici MA, Nolin TD. Kidney function assessment and its role in drug development, review and utilization. Expert Review of Clinical Pharmacology. 7: 523-32. PMID 24875237 DOI: 10.1586/17512433.2014.922865 |
0.376 |
|
| 2014 |
Ghannoum M, Bouchard J, Nolin TD, Ouellet G, Roberts DM. Hemoperfusion for the treatment of poisoning: technology, determinants of poison clearance, and application in clinical practice. Seminars in Dialysis. 27: 350-61. PMID 24823936 DOI: 10.1111/Sdi.12246 |
0.303 |
|
| 2014 |
Goldstein SL, Nolin TD. Lack of drug dosing guidelines for critically ill patients receiving continuous renal replacement therapy Clinical Pharmacology and Therapeutics. 96: 159-161. PMID 24810205 DOI: 10.1038/Clpt.2014.102 |
0.387 |
|
| 2014 |
Yates C, Galvao T, Sowinski KM, Mardini K, Botnaru T, Gosselin S, Hoffman RS, Nolin TD, Lavergne V, Ghannoum M. Extracorporeal treatment for tricyclic antidepressant poisoning: recommendations from the EXTRIP Workgroup. Seminars in Dialysis. 27: 381-9. PMID 24712820 DOI: 10.1111/Sdi.12227 |
0.322 |
|
| 2014 |
Joy MS, Frye RF, Nolin TD, Roberts BV, La MK, Wang J, Brouwer KL, Dooley MA, Falk RJ. In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy. 34: 114-22. PMID 24038489 DOI: 10.1002/Phar.1347 |
0.414 |
|
| 2013 |
Singh T, Maw TT, Henry BL, Pastor-Soler NM, Unruh ML, Hallows KR, Nolin TD. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clinical Journal of the American Society of Nephrology : Cjasn. 8: 1533-9. PMID 23704302 DOI: 10.2215/Cjn.01570213 |
0.357 |
|
| 2013 |
Peng ZY, Zhou F, Wang HZ, Wen XY, Nolin TD, Bishop JV, Kellum JA. The anti-oxidant effects are not the main mechanism for glutamine's protective effects on acute kidney injury in mice. European Journal of Pharmacology. 705: 11-9. PMID 23454558 DOI: 10.1016/J.Ejphar.2013.02.028 |
0.319 |
|
| 2012 |
Lavergne V, Nolin TD, Hoffman RS, Roberts D, Gosselin S, Goldfarb DS, Kielstein JT, Mactier R, Maclaren R, Mowry JB, Bunchman TE, Juurlink D, Megarbane B, Anseeuw K, Winchester JF, et al. The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology. Clinical Toxicology (Philadelphia, Pa.). 50: 403-13. PMID 22578059 DOI: 10.3109/15563650.2012.683436 |
0.308 |
|
| 2012 |
Pfister M, Nolin TD, Arya V. Optimizing drug development and use in patients with kidney disease: opportunities, innovations, and challenges. Journal of Clinical Pharmacology. 52: 4S-6S. PMID 22232753 DOI: 10.1177/0091270011415414 |
0.382 |
|
| 2012 |
Naud J, Nolin TD, Leblond FA, Pichette V. Current understanding of drug disposition in kidney disease. Journal of Clinical Pharmacology. 52: 10S-22S. PMID 22232747 DOI: 10.1177/0091270011413588 |
0.434 |
|
| 2011 |
Nyman HA, Dowling TC, Hudson JQ, Peter WL, Joy MS, Nolin TD. Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy. 31: 1130-44. PMID 22026399 DOI: 10.1592/Phco.31.11.1130 |
0.388 |
|
| 2011 |
Nolin TD, Arya V, Sitar DS, Pfister M. Optimizing drug development and use in patients with kidney disease. Journal of Clinical Pharmacology. 51: 628-30. PMID 21525394 DOI: 10.1177/0091270011402500 |
0.385 |
|
| 2010 |
Nolin TD, Unruh ML. Clinical relevance of impaired nonrenal drug clearance in ESRD. Seminars in Dialysis. 23: 482-5. PMID 21069923 DOI: 10.1111/J.1525-139X.2010.00775.X |
0.349 |
|
| 2010 |
Nolin TD. On warfarin use in kidney disease: a therapeutic window of opportunity? American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 56: 805-8. PMID 20970020 DOI: 10.1053/J.Ajkd.2010.09.007 |
0.336 |
|
| 2010 |
Momper JD, Venkataramanan R, Nolin TD. Nonrenal drug clearance in CKD: Searching for the path less traveled. Advances in Chronic Kidney Disease. 17: 384-91. PMID 20727508 DOI: 10.1053/J.Ackd.2010.05.009 |
0.422 |
|
| 2010 |
Boongird S, Shah N, Nolin TD, Unruh ML. Nocturia and aging: diagnosis and treatment. Advances in Chronic Kidney Disease. 17: e27-40. PMID 20610352 DOI: 10.1053/J.Ackd.2010.04.004 |
0.314 |
|
| 2010 |
Nolin TD, Ouseph R, Himmelfarb J, McMenamin ME, Ward RA. Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. Clinical Journal of the American Society of Nephrology : Cjasn. 5: 1588-94. PMID 20538838 DOI: 10.2215/Cjn.00210110 |
0.337 |
|
| 2010 |
Gupta G, Unruh ML, Nolin TD, Hasley PB. Primary care of the renal transplant patient. Journal of General Internal Medicine. 25: 731-40. PMID 20422302 DOI: 10.1007/S11606-010-1354-5 |
0.301 |
|
| 2010 |
Nolin TD, Himmelfarb J. Mechanisms of drug-induced nephrotoxicity. Handbook of Experimental Pharmacology. 111-30. PMID 20020261 DOI: 10.1007/978-3-642-00663-0_5 |
0.372 |
|
| 2009 |
Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. Journal of the American Society of Nephrology : Jasn. 20: 2269-76. PMID 19696225 DOI: 10.1681/Asn.2009010082 |
0.385 |
|
| 2009 |
Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, Townsend R, Okparavero A, Zhang YL, Schmid CH, Levey AS. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 54: 33-42. PMID 19446939 DOI: 10.1053/J.Ajkd.2009.03.008 |
0.344 |
|
| 2009 |
Stevens LA, Nolin T, Levey AS. In Reply to ‘Estimated GFR for Drug Dosing: A Bedside Formula’, ‘Drug Dose Adjustments in Patients With Renal Impairment’, ‘Use of the MDRD Study Equation for Drug Dosing’, and ‘Estimated GFR vs Creatinine Clearance for Drug Dosing’ American Journal of Kidney Diseases. 54: 985-986. DOI: 10.1053/J.Ajkd.2009.08.017 |
0.379 |
|
| 2008 |
Nolin TD. Altered nonrenal drug clearance in ESRD. Current Opinion in Nephrology and Hypertension. 17: 555-9. PMID 18941346 DOI: 10.1097/Mnh.0B013E3283136732 |
0.434 |
|
| 2008 |
Michaud J, Nolin TD, Naud J, Dani M, Lafrance JP, Leblond FA, Himmelfarb J, Pichette V. Effect of hemodialysis on hepatic cytochrome P450 functional expression. Journal of Pharmacological Sciences. 108: 157-63. PMID 18845914 DOI: 10.1254/Jphs.08042Fp |
0.308 |
|
| 2008 |
Nolin T, Naud J, Leblond F, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clinical Pharmacology & Therapeutics. 83: 898-903. PMID 18388866 DOI: 10.1038/Clpt.2008.59 |
0.409 |
|
| 2007 |
Rubin C, Nolin TD, Himmelfarb J. Are biomarkers useful for assessing cardiovascular risk in patients with chronic kidney disease? Current Opinion in Nephrology and Hypertension. 16: 506-11. PMID 18089962 DOI: 10.1097/Mnh.0B013E3282F0B331 |
0.345 |
|
| 2006 |
Owens RC, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 43: 1603-11. PMID 17109296 DOI: 10.1086/508873 |
0.323 |
|
| 2006 |
Nolin TD, Appiah K, Kendrick SA, Le P, McMonagle E, Himmelfarb J. Hemodialysis acutely improves hepatic CYP3A4 metabolic activity Journal of the American Society of Nephrology. 17: 2363-2367. PMID 16899515 DOI: 10.1681/Asn.2006060610 |
0.314 |
|
| 2003 |
Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Frye RF. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies. Clinical Pharmacology and Therapeutics. 74: 555-68. PMID 14663458 DOI: 10.1016/J.Clpt.2003.09.003 |
0.361 |
|
| 2003 |
Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 42: 906-25. PMID 14582035 DOI: 10.1016/J.Ajkd.2003.07.019 |
0.437 |
|
| 2003 |
Nolin TD, Gastonguay MR, Bies RR, Matzke GR, Bernardo JF, Aslam N, Frye RF. Population Pharmacokinetic Model of Chlorzoxazone and 6-Hydroxychlorzoxazone in Renal Failure: Impact of Patient Covariates on CYP2E1 Activity Clinical Pharmacology & Therapeutics. 73: P80-P80. DOI: 10.1016/S0009-9236(03)90654-0 |
0.313 |
|
| Show low-probability matches. |